Restart Life Sciences Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steve Loutskou
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 700-838 West Hasting Street Vancouver BC Canada V6C 0A6
- IPO Date
- Oct 19, 2011
- CIK
- 0001689231
- Website
- restartlife.co
- Similar Companies
- Business
- Restart Life Sciences Corp. (NMLSF) develops and commercializes innovative therapies focused on mitochondrial dysfunction and age-related diseases. The company offers a pipeline of small molecule drug candidates targeting conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders; its lead product, RESTART-001, is a novel mitochondrial modulator in preclinical development for cognitive impairment. Additional services include research collaborations and licensing agreements for proprietary compounds derived from its Restart platform technology. Founded in 2022 and headquartered in Vancouver, Canada, Restart Life Sciences operates primarily in North America with expansion into European clinical trial networks targeting biotech investors and pharmaceutical partners. In late 2024, the company completed a C$15 million Series A funding round led by LifeSci Venture Partners to advance RESTART-001 into Phase 1 trials; it also announced a strategic partnership with the University of British Columbia for mitochondrial biomarker validation. These developments mark a significant shift from early-stage discovery to clinical advancement, with no major acquisitions or name changes reported in the past two years.
Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks
Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap
Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY
Restart Life Advances AI-Driven E-Commerce Strategy to Scale Online Sales Growth for Holy Crap Foods
Restart Life Subsidiary Holy Crap Foods Marks New International Expansion Milestone with Bahamas On-Demand App Launch
Restart Life Sciences Appoints Inez Ho as Chief Financial Officer
Restart Life Sciences Closes Dedicated Purchase Order Financing Private Placement; CEO Subscribes for 50% of Offering
Restart Life Sciences Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio
Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market
Restart Life Sciences Announces Dedicated Purchase Order Financing Through Private Placement Offering
Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio
Restart Life Sciences Appoints Capital Markets Veteran Lindsay Hamelin to Board of Directors
Restart Life Sciences Reports Holy Crap Foods Revenue Gains of 46% in Wholesale and 32% via Amazon Channels YoY
Restart Life Advances Holy Crap Growth Strategy with New Protein SKU Nearing Commercialization
Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Launches on Walmart Canada's Digital Marketplace
Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption
Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio
Restart Life Highlights Certified Manufacturing Platform to Drive Margin Expansion and Distribution Growth
Restart Life Announces Collaboration with University of Manitoba's Centre for Food Technology and Research
Restart Life Sciences Closes Acquisition of Holy Crap Foods